Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Valeant Pharmaceuticals International Inc (NYSE:VRX)

20.00
Delayed Data
As of Jun 28
 +1.27 / +6.78%
Today’s Change
18.55
Today|||52-Week Range
263.81
-80.32%
Year-to-Date
Forget Valeant, Invest in These Attractive Drug Stocks Instead
Jun 28 / Zacks.com - Paid Partner Content
We Like Valeant Pharmaceuticals for a Trade (Video)
Jun 24 / Investing Channel - Paid Partner Content
14 Toxic Must-Sell Investments That Will Be Hit Hardest by Brexit
Jun 28 / TheStreet.com - Paid Partner Content
Steve Mandel Exits Position in Williams Companies in 1st Quarter
Jun 24 / GuruFocus News - Paid Partner Content
3 Stocks on my Brexit Shopping List
Jun 28 / TheStreet.com - Paid Partner Content
This Merger Could Mean Returns Of Up To 40%
Jun 24 / StreetAuthority - Paid Partner Content
Trade-Ideas: Valeant Pharmaceuticals International (VRX) Is Today's "Dead Cat Bounce"...
Jun 28 / TheStreet.com - Paid Partner Content
Better Buy: Valeant Pharmaceuticals International, Inc. vs. Allergan
Jun 23 / MotleyFool.com - Paid Partner Content
Valeant (VRX) Stock Tumbles, Analysts' Concerns Mount After Brexit
Jun 27 / TheStreet.com - Paid Partner Content
Forget a 'Flash Crash'; How About a 'Flash Squeeze' Instead?
Jun 23 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close18.73
Today’s open19.37
Day’s range19.17 - 20.30
Volume24,809,884
Average volume (3 months)31,907,645
Market cap$6.4B
Dividend yield--
Data as of 4:00pm ET, 06/28/2016

Growth & Valuation

Earnings growth (last year)-131.25%
Earnings growth (this year)-34.39%
Earnings growth (next 5 years)+9.00%
Revenue growth (last year)+26.42%
P/E ratioNM
Price/Sales3.32
Price/Book1.09

Competitors

 Today’s
change
Today’s
% change
ALKSAlkermes Plc+2.59+6.47%
MNKMallinckrodt Plc+2.18+4.03%
TAROTaro Pharmaceutical ...+3.26+2.37%
SGENSeattle Genetics Inc+2.40+6.60%
Data as of 4:02pm ET, 06/28/2016

Financials

Next reporting dateJuly 28, 2016
EPS forecast (this quarter)$1.62
Annual revenue (last year)$10.4B
Annual profit (last year)-$291.7M
Net profit margin-2.79%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chairman &
Chief Executive Officer
Joseph C. Papa
Chief Financial Officer, Director &
Senior VP
Robert L. Rosiello
Corporate headquarters
Laval, Quă©bec

Forecasts

Partner Offers

Search for Jobs